A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease
PHASE3CompletedINTERVENTIONAL
Enrollment
653
Participants
Timeline
Start Date
February 28, 1997
Study Completion Date
December 31, 1998
Conditions
Alzheimer DiseaseDementia
Interventions
DRUG
galantamine hydrobromide
All Listed Sponsors
lead
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
INDUSTRY
NCT00253188 - A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease | Biotech Hunter | Biotech Hunter